Prospective Grant of Exclusive Patent License: Chimeric Antigen Receptors Targeting CD56, 16602 [2021-06474]
Download as PDF
<![CDATA[
16602
Federal Register / Vol. 86, No. 59 / Tuesday, March 30, 2021 / Notices
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; New Investigator
Gateway Awards for Collaborative T1D
Research Special Emphasis Panel.
Date: April 6, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Video
Meeting).
Contact Person: Peter J. Kozel, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7009,
6707 Democracy Boulevard, Bethesda, MD
20892–5452, (301) 594–4721, kozelp@
mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–06470 Filed 3–29–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Chimeric Antigen Receptors
Targeting CD56
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute
(NCI), National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive, sublicensable patent
license to Memorial Sloan Kettering
Cancer Center, (‘‘MSKCC’’), a non-profit
research center located in New York, in
its rights to the inventions and patents
listed in the SUPPLEMENTARY
INFORMATION section of this notice.
DATES: Only written comments and/or
applications for a license which are
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:59 Mar 29, 2021
Jkt 253001
received by the NCI Technology
Transfer Center April 14, 2021 will be
considered.
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Rose M. Freel, Ph.D., Senior
Licensing and Patenting Manager at
Telephone: (301) 624–8775 or Email:
rose.freel@nih.gov.
ADDRESSES:
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to MSKCC: U.S. Provisional
Patent Application No. 62/199,775, filed
July 31, 2015 entitled ‘‘Antigen-Binding
Proteins Targeting CD56 And Uses
Thereof,’’ (HHS Ref. No. E–142–2014–0–
US–01); PCT Application No. PCT/
US16/045027, filed August 2, 2016
entitled ‘‘Antigen-binding proteins
targeting CD56 and uses thereof’’ (HHS
Ref. No. E–142–2014–0–PCT–02); U.S.
Patent No. 10,730,941, granted on
August 4, 20201, corresponding to U.S.
Patent Application No. 15/884,608, filed
January 31, 2018, entitled ‘‘Antigenbinding proteins targeting CD56 and
uses thereof’’ (HHS Ref. No. E–142–
2014–0–US–03); Canadian Patent
Application No. 2994412, filed January
31, 2018, entitled ‘‘Antigen-binding
proteins targeting CD56 and uses
thereof’’ (HHS Ref. No. E–142–2014–0–
CA–04); Australian Patent Application
No. 16833684.0, filed January 31, 2018,
entitled ‘‘Antigen-binding proteins
targeting CD56 and uses thereof’’ (HHS
Ref. No. E–142–2014–0–AU–05); U.S.
Patent Application No. 16/912,291, filed
June 25, 2020, entitled ‘‘Methods of
treatments using antigen-binding
proteins targeting CD56’’ (HHS Ref. No.
E–142–2014–0–US–06).
The patent rights in these inventions
have been assigned to the Government
of the United States of America and
Memorial Sloan Kettering Cancer
Center. The prospective patent license
will be for the purpose of consolidating
the patent rights to MSKCC, one of the
co-owners of said rights, for commercial
development and marketing.
Consolidation of these co-owned rights
is intended to expedite development of
the invention, consistent with the goals
of the Bayh-Dole Act codified as 35
U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by MSKCC will be
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
subject to the provisions of 37 CFR part
401 and 404.
The invention pertains to novel
antibody binders and chimeric antigen
receptors (CARs) that target CD56 or
NCAM, a glycoprotein that is highly
expressed in a variety of cancerous
cells. Based on current available data,
the intended use for the invention is
anti-CD56 CARs for the treatment of
CD56 positive cancers such as multiple
myeloma.
This notice is made pursuant to 35
U.S.C. 209 and 37 CFR part 404. The
prospective exclusive patent license
will include terms for the sharing of
royalty income with NCI from
commercial sublicenses of the patent
rights and may be granted unless within
fifteen (15) days from the date of this
published notice the NCI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C
§ 552.
Dated; March 10, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2021–06474 Filed 3–29–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
SUMMARY:
E:\FR\FM\30MRN1.SGM
30MRN1
]]>Agencies
[Federal Register Volume 86, Number 59 (Tuesday, March 30, 2021)]
[Notices]
[Page 16602]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06474]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Chimeric Antigen
Receptors Targeting CD56
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute (NCI), National Institutes of
Health, Department of Health and Human Services, is contemplating the
grant of an exclusive, sublicensable patent license to Memorial Sloan
Kettering Cancer Center, (``MSKCC''), a non-profit research center
located in New York, in its rights to the inventions and patents listed
in the SUPPLEMENTARY INFORMATION section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the NCI Technology Transfer Center April 14, 2021 will
be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Rose M. Freel, Ph.D., Senior Licensing and
Patenting Manager at Telephone: (301) 624-8775 or Email:
[email protected].
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to MSKCC:
U.S. Provisional Patent Application No. 62/199,775, filed July 31, 2015
entitled ``Antigen-Binding Proteins Targeting CD56 And Uses Thereof,''
(HHS Ref. No. E-142-2014-0-US-01); PCT Application No. PCT/US16/045027,
filed August 2, 2016 entitled ``Antigen-binding proteins targeting CD56
and uses thereof'' (HHS Ref. No. E-142-2014-0-PCT-02); U.S. Patent No.
10,730,941, granted on August 4, 20201, corresponding to U.S. Patent
Application No. 15/884,608, filed January 31, 2018, entitled ``Antigen-
binding proteins targeting CD56 and uses thereof'' (HHS Ref. No. E-142-
2014-0-US-03); Canadian Patent Application No. 2994412, filed January
31, 2018, entitled ``Antigen-binding proteins targeting CD56 and uses
thereof'' (HHS Ref. No. E-142-2014-0-CA-04); Australian Patent
Application No. 16833684.0, filed January 31, 2018, entitled ``Antigen-
binding proteins targeting CD56 and uses thereof'' (HHS Ref. No. E-142-
2014-0-AU-05); U.S. Patent Application No. 16/912,291, filed June 25,
2020, entitled ``Methods of treatments using antigen-binding proteins
targeting CD56'' (HHS Ref. No. E-142-2014-0-US-06).
The patent rights in these inventions have been assigned to the
Government of the United States of America and Memorial Sloan Kettering
Cancer Center. The prospective patent license will be for the purpose
of consolidating the patent rights to MSKCC, one of the co-owners of
said rights, for commercial development and marketing. Consolidation of
these co-owned rights is intended to expedite development of the
invention, consistent with the goals of the Bayh-Dole Act codified as
35 U.S.C. 200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
MSKCC will be subject to the provisions of 37 CFR part 401 and 404.
The invention pertains to novel antibody binders and chimeric
antigen receptors (CARs) that target CD56 or NCAM, a glycoprotein that
is highly expressed in a variety of cancerous cells. Based on current
available data, the intended use for the invention is anti-CD56 CARs
for the treatment of CD56 positive cancers such as multiple myeloma.
This notice is made pursuant to 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license will include terms for the
sharing of royalty income with NCI from commercial sublicenses of the
patent rights and may be granted unless within fifteen (15) days from
the date of this published notice the NCI receives written evidence and
argument that establishes that the grant of the license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C Sec. 552.
Dated; March 10, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2021-06474 Filed 3-29-21; 8:45 am]
BILLING CODE 4140-01-P
